Dexcom Reports Second Quarter 2024 Financial Results, Updates …

Jul 25, 2024 · DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% …

CouponFollow Extension

15%
OFF

Dexcom Reports Second Quarter 2024 Financial Results, Updates …

1 week from now

Jul 25, 2024 · DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% …

dexcom.com

15%
OFF

Dexcom Reports Second Quarter 2024 Financial Results, Updates …

1 week from now

Second Quarter 2024 Financial Results. Revenue: In the second quarter of 2024, worldwide revenue grew 15% to $1.004 billion on a reported basis, up from $871.3 million in the second …

morningstar.com

15%
OFF

Dexcom Reports Second Quarter 2024 Financial Results, Updates …

1 week from now

Jul 25, 2024 · DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% …

wallstreet-online.de

$994
OFF

Dexcom Reports Third Quarter 2024 Financial Results

1 week from now

Oct 24, 2024 · 1. Third quarter 2024 organic revenue was $994.7 million and excludes $0.5 million of foreign exchange impact. Third quarter 2023 reported revenue included $8.0 million …

morningstar.com

2%
OFF

Dexcom Reports Third Quarter 2024 Financial Results

1 week from now

Oct 24, 2024 · For the third quarter of 2024, Dexcom reported a revenue of $994.2 million, reflecting a 2% year-over-year increase on a reported basis and a 3% increase on an organic …

tradingview.com

24%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · For the third quarter ended September 30, 2024, scPharmaceuticals reports: Net FUROSCIX revenue of $10.0 million, representing a 24% increase from the second quarter of …

nasdaq.com

$1
OFF

Alpha Cognition Announces Financial Results For The Second …

1 week from now

2 days ago · The third quarter of 2024 net loss was $1.9 million, or a net loss of $0.31 per share, and for the full nine months ended September 30, 2024, net loss was $9.0 million, or a net loss …

morningstar.com

24%
OFF

Dexcom Reports First Quarter 2024 Financial Results

1 week from now

Mar 31, 2024 · DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% …

dexcom.com

$750
OFF

Dexcom Reports Second Quarter 2024 Financial Results, Updates …

1 week from now

Jul 25, 2024 · The company also announced a $750 million share repurchase program in conjunction with second quarter results. Second Quarter 2024 Financial Results. Revenue: In …

marketscreener.com

81%
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

5 days ago · Third Quarter 2024 Financial Highlights Total net product revenue for the third quarter of 2024 was $104.8 million, representing 81% year-over-year growth. Total net product …

yahoo.com

15%
OFF

Dexcom Reports Second Quarter 2024 Financial Results, Updates …

1 week from now

Jul 25, 2024 · DexCom, Inc. today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year …

marketscreener.com

FAQs about Dexcom Reports Second Quarter 2024 Financial Results, Updates … Coupon?

How did Dexcom perform in the second quarter 2024?

SAN DIEGO-- (BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic 1 basis. ...

Is Dexcom reiterating guidance for fiscal year 2024?

Dexcom is updating fiscal year 2024 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: First Quarter 2024 Financial Results ...

How did Revenue perform in the second quarter 2024?

Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic 1 basis. U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic 1 basis, all on a year-over-year basis. ...

What is Dexcom's 2024 organic growth expectation?

Dexcom's 2024 organic growth expectation excludes approximately $30 million of fiscal year 2023 revenue related to the divestiture of certain non-CGM assets. * See Table E below for a reconciliation of these GAAP and non-GAAP financial measures. Conference Call Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). ...

How much cash does Dexcom hold?

Cash and Liquidity: As of June 30, 2024, Dexcom held $3.12 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities. ...

How did CGM perform in the second quarter of 2024?

Revenue: In the second quarter of 2024, worldwide revenue grew 15% to $1.004 billion on a reported basis, up from $871.3 million in the second quarter of 2023. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases. ...